Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer

Kohei Shitara

Elena Elimova

Princess Margaret Cancer Centre, Toronto

Tianshu Liu

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai

Josep Tabernero

Vall d’Hebron Hospital Campus, Barcelona

Keun-Wook Lee

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea

Michael Schenker

Department of Oncology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Niall C. Tebbutt

Jaffer Ajani

University of Texas M.D. Anderson Cancer Center, Houston

Norhidayu Salimin

National Cancer Institute, Putrajaya, Malaysia

Geoffrey Ku

Memorial Sloan Kettering Cancer Center, New York

Jong Gwang Kim

Inmaculada Ales Diaz

Hospital Regional Universitario de Malaga, Malaga, Spain

Jingdong Zhang

Filippo Pietrantonio

Li-Yuan Bai

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

Samuel Le Sourd

Department of Medical Oncology, Centre Eugène-Marquis, Rennes, France

Jun Zhao

Department of Thoracic Oncology Beijing Cancer Hospital Beijing China

Cinta Hierro

Catalan Institute of Oncology–Badalona, Badalona Applied Research Group in Oncology, Badalona, Spain

Andrew Kiberu

Fiona Stanley Hospital, Murdoch, WA, Australia

Filip Van Herpe

University Hospitals Leuven, Leuven, Belgium

Yuanyuan Bao

BeOne Medicines, Beijing

Hanze Zhang

Jazz Pharmaceuticals, Palo Alto, CA

Lin Yang

Vincent Li

BeOne Medicines, Beijing

Elaina M. Gartner

Jazz Pharmaceuticals, Palo Alto, CA

Ye Chen

Jonathan Grim

Jazz Pharmaceuticals, Palo Alto, CA

Sun Young Rha

Lin Shen